(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/163530 A1

(51) International Patent Classification:
A61K 31/135 (2006.01) *A61K 31/40* (2006.01)
A61K 31/136 (2006.01) *A61K 31/423* (2006.01)

(21) International Application Number:
PCT/US2021/017912

(22) International Filing Date:
12 February 2021 (12.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/976,864	14 February 2020 (14.02.2020)	US
63/032,245	29 May 2020 (29.05.2020)	US
63/146,937	08 February 2021 (08.02.2021)	US


(71) Applicant: **KSQ THERAPEUTICS, INC.** [US/US]; 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **WYLIE, Andrew Alistair**; 133 Temple Street, Newton, Massachusetts 02465 (US). **SHENKER, Solomon Martin**; 30 Crescent Road, Belmont, Massachusetts 02478 (US). **SULLIVAN, Pamela Jean**; 120 Crane Street, Dedham, Massachusetts 02026 (US). **STEGMEIER, Frank**; 20 Kinsley Road, Acton, Massachusetts 01720 (US). **CADZOW, Anne Louise**; 68 Waltham St, Apt 4, Boston, Massachusetts 02118 (US). **LIU, Hanlan**; 80 East Street, Lexington, Massachusetts 02420 (US). **SINKEVICIUS, Kerstin Wolf**; 124 Tower Road, Lincoln, Massachusetts 01773 (US).

(74) Agent: **COVERT, John M.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).


WO 2021/163530 A1

(54) Title: THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS



Formula II \ Niraparib	DMSO	3.16nM	10nM	31.6nM	100nM	316nM
DMSO	100	131	111	114	99	62
3.16nM	115	123	115	107	94	56
10nM	106	128	94	94	77	50
31.6nM	96	126	79	87	69	30
100nM	89	85	66	41	26	21
316nM	74	75	46	34	26	19

FIG. 1



(57) Abstract: The present disclosure provides therapeutic combinations comprising (i) a ubiquitin-specific-processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II), or (III), or pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, or polymorphs thereof. The present disclosure is also directed to the use of the combinations to inhibit a USP1 and/or PARP protein and/or to treat a disorder responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. The combinations of the present disclosure are especially useful for treating cancer.

[Continued on next page]

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*